Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure

The Japanese pharmaceutical company will acquire Deciphera for $2.4bn, gaining GIST treatment Qinlock (ripretinib).

magnet
ONO is gaining new assets with Deciphera • Source: Shutterstock

Ono Pharmaceutical Company, Ltd., a Japanese pharmaceutical firm, has ambitions to become a global specialty pharma company and has made a move to strengthen its geographic footprint. The company announced plans to acquire Waltham, MA-based Deciphera Pharmaceuticals, Inc. for $2.4bn, gaining a marketed cancer drug and a commercial presence in the US and Europe.

Ono revealed the acquisition on 29 April, agreeing to pay $25

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas